Anti-obesity medications, including popular GLP-1 drugs like Wegovy, may soon be included in employer-covered health insurance plans, a shift that could significantly expand access to these treatments. As open enrollment season approaches, employees will have the chance to learn whether their health insurance benefits for the coming year will include coverage for these medications, which have surged in popularity due to their effectiveness in treating both diabetes and obesity.
While drugs like Wegovy are commonly covered under insurance plans for treating diabetes, coverage for their use in addressing obesity and weight loss has been far less common. This is now beginning to change as more employers recognize the potential health benefits of addressing obesity, which can lead to a reduction in overall healthcare costs associated with obesity-related conditions such as heart disease, hypertension, and certain types of cancer.
GLP-1 drugs, which are designed to mimic a hormone that helps regulate appetite and insulin, have been shown to be highly effective in promoting significant weight loss. Their use for treating obesity is becoming more widespread as awareness grows about their potential to support long-term health improvements.
Advocates for broader coverage argue that the inclusion of anti-obesity medications in employer-sponsored plans could play a crucial role in combating the obesity epidemic in the U.S., where nearly 42% of adults are classified as obese. “Obesity is not just a cosmetic issue, it’s a medical condition with serious health implications, and these medications provide an important tool in addressing it,” said one healthcare expert.
Employees will now be paying close attention during this open enrollment period, as the decision to include coverage for these drugs could impact both their health outcomes and their out-of-pocket costs. With the high price of these medications—Wegovy, for example, can cost over $1,300 per month—many employees may find access limited without insurance coverage.
As the conversation around employer-covered anti-obesity medications grows, the potential for long-term savings on healthcare costs and improved health outcomes may lead more companies to consider including these treatments in their health plans.
Photo by Towfiqu barbhuiya: https://www.pexels.com/photo/a-person-holding-his-belly-fat-9927899/
